Management of TR2 Thyroid Nodules
TR2 thyroid nodules are classified as "not suspicious" and do not require fine-needle aspiration biopsy or routine follow-up imaging. 1
Understanding TR2 Classification
TR2 nodules in the ACR Thyroid Imaging Reporting and Data System represent benign-appearing lesions with minimal to no suspicious ultrasound features. 1 The evidence consistently demonstrates that:
- All TR2 nodules in multiple large studies have been benign, with no malignancies identified in this category 2, 3
- The ACR TI-RADS system achieves 98.8% specificity for identifying benign nodules when TR2 and small TR3 nodules are combined 4
- In a pediatric cohort of 18 TR2 nodules, 100% were benign 2
Recommended Management Algorithm
Initial Assessment
- No biopsy is indicated regardless of nodule size 3, 5
- No routine ultrasound follow-up is recommended for TR2 nodules 1
- Document thyroid function tests (TSH) and calcitonin levels as baseline 1
Exceptions Requiring Further Evaluation
Consider biopsy only if:
- Clinical risk factors are present: family history of thyroid cancer, history of head/neck irradiation, or syndromes associated with thyroid malignancy (MEN 2A/2B, familial adenomatous polyposis, Cowden syndrome) 1
- Compressive symptoms develop: dysphagia, voice changes, or respiratory symptoms 1
- Nodule grows to ≥2.5 cm: Some evidence suggests follow-up for TR2 nodules reaching this threshold could identify 7 additional malignancies, though this would also capture 316 additional benign nodules 3
- Autonomously functioning nodule confirmed by radionuclide imaging 1
Cost-Effectiveness Considerations
The ACR TI-RADS approach for TR2 nodules is highly cost-effective because:
- It recommends 25-50% fewer biopsies compared to ATA, EU-TIRADS, and K-TIRADS guidelines 5
- The unnecessary FNA rate is reduced to 41.4% compared to 60-69% with other systems 6
- Only 1.2% of merged TR2 and small TR3 categories showed any concerning cytology 4
Important Caveats
Pathological confirmation is still required before any ablative therapy. If a patient were to pursue thermal ablation for symptomatic reasons, the Chinese guidelines mandate that "all patients undergoing thermal ablation of thyroid nodules should perform puncture biopsy to confirm the pathological diagnosis, and FNAB is the preferred method." 1 This applies even to benign-appearing nodules.
The TR2 classification assumes proper ultrasound technique and interpretation. The nodule must lack the following suspicious features: irregular margins, taller-than-wide shape, microcalcifications, or marked hypoechogenicity. 1, 7
Interobserver agreement for TR2 classification is excellent (kappa 0.86), providing confidence in the reproducibility of this assessment 2
When Thermal Ablation Might Be Considered
For TR2 nodules that become symptomatic, thermal ablation indications per Chinese guidelines include 1:
- Nodules causing compression symptoms or cosmetic concerns
- Nodules with maximal diameter ≥2 cm
- Autonomously functioning thyroid nodules
- Recurrent nodules after chemical ablation
However, mandatory pre-ablation requirements include 1:
- Fine-needle aspiration biopsy to confirm benign pathology
- Comprehensive laboratory testing (CBC, coagulation studies, thyroid function, calcitonin)
- Contrast-enhanced ultrasound to evaluate blood supply
- Neck CT if concerns about tracheal relationship or substernal extension exist